Related Experiment Video
Updated: Aug 10, 2026
09:45
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
Do statins slow down Alzheimer's disease? A review
1The Ohio State University, Columbus, OH 43210, USA.
Journal of Clinical Pharmacy and Therapeutics
|May 22, 2004
Summary
Statins, a cholesterol-lowering drug, may decrease Alzheimer's disease (AD) incidence and Abeta peptides. However, current evidence is insufficient to recommend statins for cognitive improvement in AD patients due to a lack of data on cognitive benefits and potential side effects.
Area of Science:
- Neurology
- Pharmacology
- Epidemiology
Background:
- Alzheimer's disease (AD) affects over 4 million Americans, with prevalence increasing significantly with age.
- Epidemiological studies suggest a potential decrease in AD incidence with the use of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins).
- Statins have shown potential in reducing Abeta peptides, a key hallmark of AD.
Purpose of the Study:
- To evaluate the existing evidence on the use of statins for cognitive benefits in Alzheimer's disease patients.
- To investigate the potential impact of statins on AD incidence and Abeta peptide levels.
- To assess concerns regarding statin side effects, particularly those crossing the blood-brain barrier.
Main Methods:
- Review of epidemiological studies and published research on statin use in relation to Alzheimer's disease.
- Analysis of data concerning statin effects on Abeta peptides and cognitive function.
- Examination of reported adverse events associated with statin use in the context of AD.
Main Results:
- Some studies indicate statins may decrease AD incidence and Abeta peptides.
- Data regarding the cognitive benefits of statins in AD patients is currently lacking.
- Concerns exist about potential side effects of statins crossing the blood-brain barrier, though adverse events are infrequently reported.
Conclusions:
- There is insufficient evidence to support the use of statins for cognitive improvements in patients with Alzheimer's disease.
- Further research is needed to clarify the cognitive benefits and safety profile of statins in the AD population.
- The potential impact of statins on AD progression and side effects requires more comprehensive investigation.
More Related Videos
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
09:15Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:23Atherosclerosis IV: Nursing Management
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...